Anzeige
Mehr »
Login
Dienstag, 21.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News! 22 Jahre "BlueChip"-Power nun bei NurExone!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12EV9 | ISIN: US2681582019 | Ticker-Symbol: DYF1
Tradegate
20.05.24
08:00 Uhr
10,500 Euro
-0,010
-0,10 %
1-Jahres-Chart
DYNAVAX TECHNOLOGIES CORPORATION Chart 1 Jahr
5-Tage-Chart
DYNAVAX TECHNOLOGIES CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
10,33010,65020.05.
0,0000,00020.05.

Aktuelle News zur DYNAVAX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiFDA rejects label expansion for Dynavax's hepatitis B vaccine3
14.05.FDA Declines To Approve Expanded Use of Dynavax's Hepatitis B Vaccine In Hemodialysis Patients4
14.05.Dynavax falls as FDA declines expanded use of hepatitis B vaccine in dialysis patients2
14.05.Dynavax Technologies: Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B Regimen for Adults on Hemodialysis in the U.S.91EMERYVILLE, Calif., May 14, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today provided a regulatory update for the Company's supplemental Biologics License Application...
► Artikel lesen
09.05.Earnings call: Dynavax forecasts robust HEPLISAV-B sales, pipeline growth6
09.05.Dynavax Technologies Corporation (DVAX) Q1 2024 Earnings Call Transcript2
08.05.Dynavax drops 6% as quarterly results miss on both lines3
08.05.DYNAVAX TECHNOLOGIES CORP - 10-Q, Quarterly Report2
08.05.Dynavax GAAP EPS of -$0.07 misses by $0.04, revenue of $50.79M misses by $4.19M4
08.05.DYNAVAX TECHNOLOGIES CORP - 8-K, Current Report1
08.05.Dynavax Technologies: Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates76HEPLISAV-B® vaccine net product revenue grew 10% year-over-year to approximately $48 million in the first quarter of 2024 Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265...
► Artikel lesen
12.03.DYNAVAX TECHNOLOGIES CORP - 8-K, Current Report3
23.02.Earnings call: Dynavax reports record revenue growth in 202315
22.02.DYNAVAX TECHNOLOGIES CORP - 10-K, Annual Report6
22.02.Dynavax Technologies: Q4 Earnings Insights10
22.02.DYNAVAX TECHNOLOGIES CORP - 8-K, Current Report3
22.02.Dynavax Technologies: Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance559HEPLISAV-B® 2023 net product revenue grew 69% year-over-year to $213 million Achieved market leader status in key segments retail pharmacy and IDNs in 2023 2024 HEPLISAV-B net product revenue expected...
► Artikel lesen
08.01.Dynavax reports 46% Y/Y increase in HEPLISAV-B vaccine net product revenue24
08.01.DYNAVAX TECHNOLOGIES CORP - 8-K, Current Report6
08.01.Dynavax Technologies: Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights342Preliminary full year 2023 HEPLISAV-B® vaccine net product revenue of approximately $213 million, a 69% year-over-year increase Significant gains in HEPLISAV-B market share in key market segments...
► Artikel lesen
Seite:  Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1